Summary To determine safety and the efficacy of carnitine treatment in children with attention-deficit hyperactivity disorder (ADHD).The ADHD behavior was observed by parents completing the Child Behavior Checklist (CBCL) and by teachers completing the Conners teacher-rating score, in a randomized, double-blind, placebo-controlled double-crossover trial. In13/24 boysreceiving carnitine, home behavior improved as assessed with the CBCL total score (Po0.02).In13/24 boys, schoolbehavior improved as assessed with the Conners teacher-rating score (Po0.05). Before treatment, the CBCL total and sub-scores were significantly different from those of normal Dutch boys (Po0.0001). Responders showed a significant improvement of the CBCL total scores compared to baseline (Po0.0001). In the majority of boys no side effects were seen. At baseline and after carnitine treatment, responders showed higher levels of plasma-free carnitine (Po0.03) and acetylcarnitine (Po0.05). Compared to baseline, the carnitine treatment causedin the responsive patients a decrease of 20^65% (8^48 points) as assessed by the CBCL totalproblemrating scale.Treatment with carnitine significantlydecreased the attention problems and aggressive behavior in boys with ADHD. &
INTRODUCTION
The attention-deficit hyperactivity disorder (ADHD) is a neurobehavioral predominantly inheritable disorder with a spectrum of problematic behavior, 1 possibly caused by structural or functional abnormalities in the connections between the frontal cortex and the basal ganglia. 2 It is the most common psychiatric disorder in children and the symptoms often persist into adolescence and adulthood. 2 Available literature indicates an important role of stimulant medication in improving abnormal behavior, cognitive and social function in ADHD. The use of stimulating drugs may be associated with adverse side effects. 3 Tricyclic antidepressants (TCA), non-TCA antidepressants, clonidine and bupropion are also used widely. Improvement in behavior during treatment with these drugs is reported, having a mostly moderate and sometimes robust response. 4 Preliminary experience in our hospital suggested that carnitine is a safe alternative drug to treat the condition. In two families we diagnosed a low plasma carnitine level (20 mmol/l) and ADHD behavior in four children. A trial treatment of these children with 100 mg carnitine/ (kg day), twice daily, caused a decrease in their hyperactive impulsive behavior. After cessation of the carnitine medication, the abnormal behavior returned within 3-4 weeks, and reintroduction of carnitine improved their behavior again. Carnitine treatment also improved the condition of five other children with ADHD, who did not respond to methylphenidate or clonidine or other psychiatric treatment (unpublished data).
L-Carnitine is a small water-soluble molecule and has an important role in metabolism as carrier of activated fatty acids. It is indispensable for the oxidation of longchain fatty acids by mitochondria, stimulates the oxidation of pyruvate and branched-chain 2-keto fatty acids and decreases acyl-CoA levels. Acetylcarnitine is a highenergy reservoir in equilibrium with the intracellular acetyl-CoA pool. Acetyl-CoA may be oxidized by the Krebs cycle for energy production, or act as acetyl donor for fatty acid synthesis or elongation, and for the synthesis of steroids and acetylcholine.
Arduini and co-workers demonstrated that the carnitine system is involved in membrane repair by acyl delivery in the cell, including the neurons. 5 The transport of carnitine to the brain is a slow process due to a low affinity. 6 PET studies in rats with labeled acetylcarnitine,
showed that mainly carbon from acetyl is transported to the brain, 7 and that the metabolism of the acetyl group in brain differs from that of glucose. Acetylcarnitine is more efficiently incorporated into polyunsaturated fatty acid, which is an important constituent of brain phospholipids. 8, 9 In rodent brain, acetylcarnitine was reported to attenuate the neurological damage 10 and to improve energy metabolism 11 after ischemia and reperfusion, to normalize the age-related impairment of several receptor systems 12 and the membrane phospholipid metabolism 13 and also to treat hyperactivity. 14 Recently, the hyperactive behavior of patients with the fragile X syndrome was successfully treated with 50 mg/ (kg day) acetylcarnitine in a placebo-controlled study. 15 The objective of this study was to whether the earlier observed effect of carnitine treatment could be confirmed in a controlled study of carnitine vs placebo in a new group of ADHD patients.
PATIENTS AND METHODS
This was a randomized, double-blind, placebo-controlled double-crossover study conducted at the pediatrics outpatient clinic. The double crossover design was chosen because, during pre-trial observations, cessation and reintroduction of carnitine was followed by deterioration and improvement in behavior, respectively. No carry-over effect was observed during pre-trial observations.
At first, the boys were screened and examined by the pediatrician. Then, the boys were extensively examined and interviewed by the child psychiatrist or child psychologist to confirm the ADHD diagnosis and to rule out any serious co-morbidity (psychosis, depression, autism).
The inclusion criteria were (1) boys aged between 6 and 13 years, outpatients living in a family home; (2) a diagnosis of ADHD according to DSM IV American Psychiatric Association (Diagnostic and Statistical Manual of Mental Disorders) 16 for the combined group with attention deficit/hyperactivity/impulsiveness based on the combined use of clinical interview of child psychiatrist, child psychologist and pediatrician according to their routine procedures and a Child Behavior Checklist (CBCL) score in the clinical area on the total score or at least one the following sub-scores: attention problems, delinquency and aggressive behavior 17, 18 as recommended by the Dutch Psychiatric Association; 19 (3) not receiving any stimulant medication; (4) attending normal elementary school; (5) healthy on physical examination and laboratory tests; (6) written informed consent was obtained from the parents. The exclusion criteria were (1) heart disease, impaired renal function (plasma creatinine 470 mmol/l), impaired liver function (plasma g-GT440 U/l), diabetes mellitus; (2) treatment with b 3 -sympatico-mimetics and/or parasympaticolytics for chronic obstructive lung disease and bronchial asthma; (3) important changes in school or home situation expected during the course of the study period; (4) psychosis or severe brain damage or other serious psychiatric disease as assessed by the child psychiatrist or psychologist; (5) any concomitant disease that might interfere with drug evaluation; (6) participation in another pharmacological study or treatment with carnitine within 1 month prior to the screening visit. Before this trial, no boy received any carnitine treatment.
Instruments and measures
As there is no objective diagnostic marker for ADHD, 1, 2 the CBCL total problem score, the CBCL attention problems sub-score, the CBCL delinquency sub-score, the CBCL aggressive behavior sub-score were used to follow the condition of the boys as assessed by the parents. According to the CBCL manual, recommending to use the total-rating score in complex behavior disorders for research purposes, the total-rating score was completed every 8 weeks. The CBCL checklist contains 120 questions with three grades of severity, and is completed by the parents. The CBCL was used to distinguish a child's behavior into normal and abnormal clinical behavior. The threshold of clinical behavior of the CBCL total problem score is above 40 points, that of the attention problem, the delinquency and aggressive behavior sub-scores is above 10, 5 and 20 points, respectively. These sub-scores match the DSM IV criteria according to the CBCL manual. For each boy, the response over time was assessed compared to baseline and a 30% decrease of the CBCL rating scale or a decrease below the clinical area was considered a responder.
The Conners Teacher 39 item rating scale was used. 20 The Conners Teacher rating scale (CTRS) analyses all behavior problems in the school situation and contains 39 items with four grades of severity. The scale was developed as a diagnostic tool and to assist at the evaluation of attention/behavior disorders. To use the rating scale as a treatment intervention tool to detect attention/behavior differences, the grades of severity are analyzed as ordered categories. A child was considered as a responder if there was a 30% decrease in the number of most severe ratings (degree 4) in a carnitine period compared to the baseline period. Each boy was assessed at the end of each trial period for the three trial periods separately.
Procedure
Approval was received for the study from the Medical Ethical Committee of the Westfries Gasthuis, Hoorn, The Netherlands. The duration of the trial was 24 weeks. Written informed consent was obtained from the parents. At the first visit 30 boys were screened, 26 patients were included in the trial as they appeared, at the pediatric outpatient department, fulfilling the inclusion criteria. These 26 eligible boys were randomly assigned, in blocks of six, to two groups. There were two groups of 13 boys each. One group received placebo-carnitine-placebo and the other group carnitine-placebo-carnitine. The three treatment periods were 8 weeks each. At the end of each period, all patients visited the pediatrician for examination.
No other medication for co-morbidity was given during the entire study. Blood samples for laboratory tests were taken at all visits except the first one. All patients received psychological counseling during and after the trial.
Medication
The investigated drug was L-carnitine, stored in drinking vials of 6 g/20 ml; the placebo had a similar look and taste. The medication was taken twice daily after meals. The carnitine dosage was 100 mg/kg daily with a maximum of 4 g. The quantity of medication was supplied for a period of 8 weeks and every 8 weeks a new quantity of medication was supplied. The remaining medication was collected by the pediatrician, and indicated a good patient compliance by calculating the difference. For emergency purposes, the investigator kept a set of codes in sealed opaque envelopes.
Safety evaluation follow-up
Laboratory tests were done at screening, in week 8, 16, and 24 for hemoglobin, hematocrit, red blood cell count, white cell count, white cell differential count, platelet count and the plasma levels of urea, creatinine, sodium, potassium, ASAT, ALAT, g-GT, alkaline phosphatase, and free and acetylcarnitine. 21 Physical examination was done at screening and in week 24.
Statistical analysis
The null hypothesis is that there is no difference in the number of responders in the placebo and carnitine period in a trial period of 8 weeks. Data analysis was done with Microsoft Excel 2000 and statistical analysis with STATA 7. The McNemar w 2 -test was used to compare the number of responders in the carnitine and placebo period. The two-sample t-test was used to calculate the significance of the difference in the CBCL total problem scores and sub-scores, and in the plasma-free carnitine and acetylcarnitine levels between responders and nonresponders at baseline and after carnitine. A difference with a P of 0.05, or smaller, was considered to be significant.
RESULTS
The trial profile is presented in Figure 1 . One boy dropped out in the first placebo period because of familial circumstances; a second one in the first carnitine period because a pungent skin odor was encountered. The baseline CBCL clinical characteristics and plasma carnitine levels of the 26 boys are described in Tables 1 and 2 . Twenty-two boys completed the three trial periods and 24 boys completed the first two periods. Two boys completed only the first two periods, one boy fainted and the other due to personal reasons. On request of the parents, these two boys were treated with carnitine in the post-trial period. After 6 months, the behavior of both boys improved to a non-clinical level as judged by the CBCL total score. The CBCL-baseline ratings (Table 1) showed total-problem scores and sub-scores for attention problems, delinquency and aggressive behavior, that are significantly different from the normal Dutch boys. 18 On the CBCL-rating scale, 13 boys were found to be a responder (Po0.02). On the CTRS, 12 boys were found to be a responder (Po0.02) ( Table 3 ). Comparing the two rating scales, 11 boys were found to be a responder on both scales during the carnitine period. Compared to baseline, responders showed a highly significant improvement of the CBCL total scores (Po0.0001) and the CBCL sub-scores of attention problems (Po0.0001), delinquency (Po0.01) and of aggressive behavior (Po0.0001), Non-responders showed no improvement (Table 4) .
Plasma-free carnitine levels were significantly different between responders and non-responders after treatment (Po0.03). Plasma acetylcarnitine levels were also significantly different between responders and non-responders after treatment (Po0.05) ( Table 5) .
The overall effect of the carnitine treatment compared to baseline was a decrease of 20-65% (8-48 points) of the baseline ratings as assessed by the CBCL-total-problem rating scale.
Adverse events
Two boys broke their arm due to their hyperactive behavior during the placebo period. One boy had a short unexplained period of fainting a few days after the onset of the placebo period following carnitine. No explanation was found. One boy had an elevated plasma creatinine level during the last placebo period, but 2 weeks after the trial, a normal level was found. Physical examination of all boys by the pediatrician at the end of the three trial periods showed no abnormalities. One patient observed 5 and the mitochondrial elongation-desaturation of (n-3) fatty acids to docosahexaenoic acid. 24, 8 In view of the latter finding, it is of interest that the concentration of this fatty acid, which is important for brain maturation and functioning, is decreased in plasma of ADHD patients. 25 Some investigators consider ADHD and its comorbidity, as a disorder of fatty acid and phospholipid metabolism. 26 We hypothesize that carnitine stimulates the synthesis of both acetylcholine and docosahexaenoic acid in certain areas of the brain involved in ADHD patients.
Limitations
We acknowledge the limitations of this pilot study, because only a small number of boys were included, and of the many aspects of ADHD behavior, only the behavior was assessed by the CBCL-and the CTRS-rating scales.
Clinical implications
Given twice daily, carnitine appeared to be effective and well tolerated for the treatment of a group of children with ADHD, that showed a significantly abnormal behavior compared to normal Dutch boys. A larger scale study will be done to investigate the effect of treatment on the many more biochemical and psychological aspects of ADHD behavior. 
